Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis

Abroad (travel likely)RecruitingPHASE3

Conditions

Paroxysmal Nocturnal Hemoglobinuria · PNH · Extravascular Hemolysis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Research Site, Saskatoon, Saskatchewan, Canada
Research Site, Paris, France
Research Site, Leeds, United Kingdom
Research Site, London, United Kingdom

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Abroad (travel likely)RecruitingPHASE3

New Brunswick, United States · Philadelphia, United States

Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Abroad (travel likely)RecruitingPHASE2, PHASE3

Tianjin, China

A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor

Paroxysmal Nocturnal Hemoglobinuria (PNH) · Persistent Anemia

Abroad (travel likely)RecruitingPHASE1, PHASE2

Toronto, Canada · Suwon, South Korea

Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis

Severe Aplastic Anemia (SAA) · Hypo-Plastic Myelodysplastic Syndrome (MDS) · Paroxysmal Nocturnal Hemoglobinuria (PNH)

Abroad (travel likely)RecruitingPHASE2

Bethesda, United States